{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:14:40Z","timestamp":1792678480592,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,4,9]],"date-time":"2014-04-09T00:00:00Z","timestamp":1397001600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1053\/j.seminoncol.2014.03.011","type":"journal-article","created":{"date-parts":[[2014,3,22]],"date-time":"2014-03-22T00:30:10Z","timestamp":1395448210000},"page":"S1-S14","source":"Crossref","is-referenced-by-count":96,"special_numbering":"S4","title":["Characterization and Management of Dermatologic Adverse Events With the NovoTTF-100A System, a Novel Anti-mitotic Electric Field Device for the Treatment of Recurrent Glioblastoma"],"prefix":"10.1053","volume":"41","author":[{"given":"Mario E.","family":"Lacouture","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Elizabeth Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Elzinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Butowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Villano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucianna","family":"DiMeglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela M.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric T.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2014.03.011_bib1","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1001\/jama.2013.280319","article-title":"Glioblastoma and other malignant gliomas: a clinical review","volume":"310","author":"Omuro","year":"2013","journal-title":"JAMA"},{"issue":"Suppl 4","key":"10.1053\/j.seminoncol.2014.03.011_bib2","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1053\/j.seminoncol.2011.09.005","article-title":"Understanding glioblastoma tumor biology: the potential to improve current diagnosis and treatments","volume":"38","author":"Kesari","year":"2011","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminoncol.2014.03.011_bib3","first-page":"221","article-title":"Advances and challenges in the treatment of glioblastoma: a clinician\u05f3s perspective","volume":"15","author":"Mrugala","year":"2013","journal-title":"Discov Med"},{"key":"10.1053\/j.seminoncol.2014.03.011_bib4","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2014.03.011_bib5","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s11060-011-0738-7","article-title":"Improved survival time trends for glioblastoma using the SEER 17 population-based registries","volume":"107","author":"Koshy","year":"2012","journal-title":"J Neurooncol"},{"key":"10.1053\/j.seminoncol.2014.03.011_bib6","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/cncr.26494","article-title":"Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of Surveillance, Epidemiology, and End Results registries","volume":"118","author":"Darefsky","year":"2012","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2014.03.011_bib7","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.2147\/OTT.S50208","article-title":"Personalized treatment strategies in glioblastoma: MGMT promoter methylation status","volume":"6","author":"Thon","year":"2013","journal-title":"Onco Targets Ther"},{"key":"10.1053\/j.seminoncol.2014.03.011_bib8","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1200\/JCO.1999.17.8.2572","article-title":"Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials","volume":"17","author":"Wong","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2014.03.011_bib9","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S0140-6736(95)90755-6","article-title":"Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group","volume":"345","author":"Brem","year":"1995","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2014.03.011_bib10","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1212\/WNL.0b013e3181bc0184","article-title":"Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma","volume":"73","author":"Iwamoto","year":"2009","journal-title":"Neurology"},{"key":"10.1053\/j.seminoncol.2014.03.011_bib11","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1215\/15228517-2009-006","article-title":"Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab","volume":"11","author":"Quant","year":"2009","journal-title":"Neuro Oncol"},{"key":"10.1053\/j.seminoncol.2014.03.011_bib12","unstructured":"Instructions for Use. NovoTTF-100A System. March 3, 2012."},{"key":"10.1053\/j.seminoncol.2014.03.011_bib13","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/j.ejca.2012.04.011","article-title":"NovoTTF-100A versus physicians\u2019 choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality","volume":"48","author":"Stupp","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2014.03.011_bib14","doi-asserted-by":"crossref","first-page":"10152","DOI":"10.1073\/pnas.0702916104","article-title":"Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors","volume":"104","author":"Kirson","year":"2007","journal-title":"PNAS"},{"key":"10.1053\/j.seminoncol.2014.03.011_bib15","first-page":"695","article-title":"Studies of thermal injury","volume":"23","author":"Moritz","year":"1947","journal-title":"Am J Pathol"},{"key":"10.1053\/j.seminoncol.2014.03.011_bib16","unstructured":"NovoTTF-100A System - P100034. Available from: http:\/\/www.fda.gov\/MedicalDevices\/ProductsandMedicalProcedures\/DeviceApprovalsandClearances\/Recently-ApprovedDevices\/ucm254480.htm"},{"key":"10.1053\/j.seminoncol.2014.03.011_bib17","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1158\/0008-5472.CAN-04-0083","article-title":"Disruption of cancer cell replication by alternating electric fields","volume":"64","author":"Kirson","year":"2004","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2014.03.011_bib18","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1517\/13543784.2011.583236","article-title":"Tumor treating fields: concept, evidence and future","volume":"20","author":"Pless","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1053\/j.seminoncol.2014.03.011_bib19","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/nyas.12112","article-title":"Tumor treating fields: a new frontier in cancer therapy","volume":"1291","author":"Davies","year":"2013","journal-title":"Ann N Y Acad Sci"},{"issue":"Suppl 6","key":"10.1053\/j.seminoncol.2014.03.011_bib20","article-title":"Mitosis interference of cancer cells by NovoTTF-100A causes decreased cellular viability [abstract]","volume":"14","author":"Lee","year":"2012","journal-title":"Neuro-Oncology (Meeting Abstracts)"},{"issue":"Suppl 3","key":"10.1053\/j.seminoncol.2014.03.011_bib21","article-title":"Mitotic interference of cancer cells during anaphase by electric field from NovoTTF-100A [abstract]","volume":"13","author":"Lee","year":"2011","journal-title":"Neuro-Oncology (Meeting Abstracts)"},{"key":"10.1053\/j.seminoncol.2014.03.011_bib22","first-page":"1","article-title":"Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields). BMC","volume":"9","author":"Kirson","year":"2009","journal-title":"Med Phys"},{"key":"10.1053\/j.seminoncol.2014.03.011_bib23","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/jnci\/djm324","article-title":"Is there room for improvement in adverse event reporting in the era of targeted therapies?","volume":"100","author":"Edgerly","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminoncol.2014.03.011_bib24","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.jaad.2012.02.010","article-title":"Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0","volume":"67","author":"Chen","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1053\/j.seminoncol.2014.03.011_bib25","unstructured":"NCI CTC Version 4.03, 2010 available at http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf"},{"key":"10.1053\/j.seminoncol.2014.03.011_bib26","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/j.1600-0625.2008.00786.x","article-title":"The skin: an indispensable barrier","volume":"17","author":"Proksch","year":"2008","journal-title":"Exp Dermatol"},{"key":"10.1053\/j.seminoncol.2014.03.011_bib27","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/emm.1999.2","article-title":"Bricks and mortar of the epidermal barrier","volume":"31","author":"Nemes","year":"1999","journal-title":"Exp Mol Med"},{"key":"10.1053\/j.seminoncol.2014.03.011_bib28","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1046\/j.1523-1747.2003.12359.x","article-title":"Barrier function of the skin: \u201cla raison d\u02bc\u00eatre\u201d of the epidermis","volume":"121","author":"Madison","year":"2003","journal-title":"J Invest Dermatol"},{"key":"10.1053\/j.seminoncol.2014.03.011_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2567.2011.03506.x","article-title":"Epithelial barrier biology: good fences make good neighbours","volume":"135","author":"Moens","year":"2012","journal-title":"Immunology"},{"key":"10.1053\/j.seminoncol.2014.03.011_bib30","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/265421a0","article-title":"Epidermal growth factor and the multiplication of cultured human epidermal keratinocytes","volume":"265","author":"Rheinwald","year":"1977","journal-title":"Nature"},{"key":"10.1053\/j.seminoncol.2014.03.011_bib31","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0965-206X(06)62005-6","article-title":"The microanatomy of the epidermis in relation to trauma","volume":"16","author":"Cruickshank","year":"2006","journal-title":"J Tissue Viability"},{"issue":"Suppl. 1","key":"10.1053\/j.seminoncol.2014.03.011_bib32","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2133.2011.10783.x","article-title":"Insights into shaving and its impact on skin","volume":"166","author":"Cowley","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1053\/j.seminoncol.2014.03.011_bib33","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.clindermatol.2013.01.014","article-title":"Contact dermatitis: facts and controversies","volume":"31","author":"Wolf","year":"2013","journal-title":"Clin Dermatol"},{"key":"10.1053\/j.seminoncol.2014.03.011_bib34","doi-asserted-by":"crossref","first-page":"6,8,10","DOI":"10.12968\/bjcn.2013.18.1.6","article-title":"Moisture-associated skin damage: an overview for community nurses","volume":"18","author":"Voegeli","year":"2013","journal-title":"Br J Community Nurs"},{"key":"10.1053\/j.seminoncol.2014.03.011_bib35","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/j.1365-2133.2011.10458.x","article-title":"New horizons for cutaneous microbiology: the role of biofilms in dermatological disease","volume":"165","author":"Vlassova","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1053\/j.seminoncol.2014.03.011_bib36","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1093\/ptj\/69.12.1014","article-title":"The biology of scar formation","volume":"69","author":"Hardy","year":"1989","journal-title":"Phys Ther"},{"key":"10.1053\/j.seminoncol.2014.03.011_bib37","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrclinonc.2009.94","article-title":"Adverse effects of anticancer agents that target the VEGF pathway","volume":"6","author":"Chen","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"issue":"Suppl 3","key":"10.1053\/j.seminoncol.2014.03.011_bib38","first-page":"2C","article-title":"Photodamaged skin: a medical or a cosmetic concern?","volume":"18","author":"Raab","year":"1990","journal-title":"J Int Med Res"},{"key":"10.1053\/j.seminoncol.2014.03.011_bib39","first-page":"93","article-title":"Revised terminology in dermatology: a call for the new millennium","volume":"137","author":"Malak","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1053\/j.seminoncol.2014.03.011_bib40","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.mcna.2005.08.008","article-title":"Allergic contact dermatitis","volume":"90","author":"Mark","year":"2006","journal-title":"Med Clin North Am"},{"key":"10.1053\/j.seminoncol.2014.03.011_bib41","series-title":"Environmental and occupational medicine","first-page":"617","article-title":"Occupational skin disease","author":"Cohen","year":"2007"},{"key":"10.1053\/j.seminoncol.2014.03.011_bib42","first-page":"215","article-title":"Impact of patch testing on dermatology-specific quality of life in patients with allergic contact dermatitis","volume":"8","author":"Rajagopalan","year":"1997","journal-title":"Am J Contact Dermat"},{"key":"10.1053\/j.seminoncol.2014.03.011_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1034\/j.1600-0536.2000.043001001.x","article-title":"Use tests: ROAT (repeated open application test)\/PUT (provocative use test): an overview","volume":"43","author":"Nakada","year":"2000","journal-title":"Contact Dermat"},{"key":"10.1053\/j.seminoncol.2014.03.011_bib44","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1684\/ejd.2009.0686","article-title":"Allergic and irritant contact dermatitis","volume":"19","author":"Nosbaum","year":"2009","journal-title":"Eur J Dermatol"},{"key":"10.1053\/j.seminoncol.2014.03.011_bib45","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nrmicro2537","article-title":"The skin microbiome","volume":"9","author":"Grice","year":"2011","journal-title":"Nat Rev Microbiol"},{"key":"10.1053\/j.seminoncol.2014.03.011_bib46","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1152\/physrev.2001.81.1.449","article-title":"Controls of hair follicle cycling","volume":"81","author":"Stenn","year":"2001","journal-title":"Physiol Rev"},{"issue":"Suppl 3","key":"10.1053\/j.seminoncol.2014.03.011_bib47","article-title":"Safety Analysis of Bevacizumab Plus NovoTTF-100A in Patients with Recurrent Malignant Gliomas. [abstract]","volume":"15","author":"Elzinga","year":"2013","journal-title":"Neuro-Oncology (Meeting Abstracts)"},{"key":"10.1053\/j.seminoncol.2014.03.011_bib48","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1046\/j.1365-2133.2000.03896.x","article-title":"The spectrum of skin disorders in abdominal stoma patients","volume":"143","author":"Lyon","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1053\/j.seminoncol.2014.03.011_bib49","first-page":"28","article-title":"External stoma and peristomal complications following radical cystectomy and ileal conduit diversion: a systematic review","volume":"56","author":"Szymanski","year":"2010","journal-title":"Ostomy Wound Manage"},{"key":"10.1053\/j.seminoncol.2014.03.011_bib50","doi-asserted-by":"crossref","first-page":"138","DOI":"10.2310\/6620.2010.09103","article-title":"Stoma dermatitis: prevalent but often overlooked","volume":"21","author":"Agarwal","year":"2010","journal-title":"Dermatitis"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775414000591?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775414000591?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,16]],"date-time":"2020-08-16T17:05:37Z","timestamp":1597597537000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775414000591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":50,"alternative-id":["S0093775414000591"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2014.03.011","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]}}}